Household net worth is a major and overlooked factor in adherence to hormonal therapy among breast cancer patients and partially explains racial disparities in quality of care. The findings suggest that physicians, health ...
Feb 24, 2015
0
31
A drug that can halve the risk of developing breast cancer in post-menopausal women has been approved for use in the UK. This drug, called anastrozole, could benefit an estimated 289,000 women in the UK who are at increased ...
Nov 9, 2023
0
0
For roughly 80% of breast cancer survivors, treatment doesn't end with surgery, radiation and chemotherapy. Instead, for the next five to 10 years, doctors recommend that they take medication to block sex hormones, which ...
Aug 28, 2023
0
3
A biomarker reflecting expression levels of two genes in tumor tissue may be able to predict which women treated for estrogen-receptor (ER)-positive breast cancer should receive a second estrogen-blocking medication after ...
Jun 29, 2013
0
0
Patients repeatedly express their concern that anti-rheumatic drugs could promote the development of breast cancer. In an autoimmune inflammatory disease such as rheumatoid arthritis (RA), the immune system attacks the body's ...
May 13, 2020
0
2
Adjuvant treatment with the bone sparing drug zoledronic acid plus hormonal therapy with the aromatase inhibitor letrozole significantly increases disease-free survival compared to tamoxifen in premenopausal women with hormone ...
Oct 22, 2018
0
1
Fulvestrant significantly increases progression-free survival in women with hormone-receptor-positive advanced breast cancer, particularly those with less aggressive lower-volume disease, researchers reported at the ESMO ...
Oct 8, 2016
0
1
The addition of zoledronic acid to adjuvant endocrine therapy increased bone mineral density and reduced the risk for disease recurrence among postmenopausal women with early hormone receptor-positive breast cancer, according ...
Dec 7, 2011
0
0
Abemaciclib (Verzenio) with endocrine therapy (tamoxifen or an aromatase inhibitor) is now approved for the adjuvant treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, ...
Mar 10, 2023
0
1
(HealthDay)—For older women with estrogen receptor (ER)-positive ductal carcinoma in situ (DCIS), initiation of aromatase inhibitors (AIs) and adherence to treatment are low, according to a study published online Oct. 25 ...
Oct 31, 2016
0
1
